A Phase 4, Multi-Center, Randomized, Open-Label Study to Evaluate the Effect of BENLYSTA (Belimumab; HGS1006) on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)

Trial Profile

A Phase 4, Multi-Center, Randomized, Open-Label Study to Evaluate the Effect of BENLYSTA (Belimumab; HGS1006) on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Nov 2016

At a glance

  • Drugs Belimumab (Primary) ; Pneumococcal vaccine; Tetanus vaccine
  • Indications Pneumococcal infections; Systemic lupus erythematosus; Tetanus
  • Focus Pharmacodynamics
  • Sponsors Human Genome Sciences
  • Most Recent Events

    • 31 Mar 2016 According to ClinicalTrials.gov reocord, the protocol has been amended to assess the efficacy of belimumab on immune response to pneumococcal vaccine only (and not on tetanus toxoid). Accordingly the purpose, endpoints and the treatment table has been amended.
    • 19 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 26 Mar 2015 Planned End Date changed from 1 May 2014 to 1 Sep 2015, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top